Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNDX Syndax Pharmaceuticals

Not Yet Opened 06-06 16:00:00 EDT

19.40

+0.19

+0.99%

盘后19.40

+0.000.00%

19:44 EDT

High19.62	Low18.65	Vol1.17M
Open19.10	D1 Closing19.21	Amplitude5.05%
Mkt Cap1.65B	Tradable Cap1.64B	Total Shares84.99M
T/O22.64M	T/O Rate1.38%	Tradable Shares84.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals","latestPrice":19.4,"timestamp":1717704000000,"preClose":19.21,"halted":0,"volume":1169561,"hourTrading":{"tag":"盘后","latestPrice":19.4,"preClose":19.4,"latestTime":"19:44 EDT","volume":248632,"amount":4823441.42,"timestamp":1717717496810},"delay":0,"floatShares":84649661,"shares":84987060,"eps":-3.242697,"marketStatus":"Not Yet Opened","change":0.19,"latestTime":"06-06 16:00:00 EDT","open":19.1,"high":19.62,"low":18.65,"amount":22637325.657644,"amplitude":0.050495,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.242697,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1717747200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1456981200000,"exchange":"NASDAQ","adjPreClose":19.21,"postHourTrading":{"tag":"盘后","latestPrice":19.4,"preClose":19.4,"latestTime":"19:44 EDT","volume":248632,"amount":4823441.42,"timestamp":1717717496810},"volumeRatio":0.890446,"impliedVol":0.1815,"impliedVolPercentile":0.0079},"requestUrl":"/m/hq/s/SNDX","defaultTab":"news","newsList":[{"id":"2441772087","title":"Buy Rating on Syndax Pharmaceuticals Backed by Revumenib’s Promising Trial Results in MSS CRC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2441772087","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441772087?lang=en_us&edition=fundamental","pubTime":"2024-06-07 08:19","pubTimestamp":1717719593,"startTime":"0","endTime":"0","summary":"Justin Zelin, an analyst from BTIG, maintained the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated price target is $3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-on-syndax-pharmaceuticals-backed-by-revumenibs-promising-trial-results-in-mss-crc-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-on-syndax-pharmaceuticals-backed-by-revumenibs-promising-trial-results-in-mss-crc-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MSS","CRC","SNDX"],"gpt_icon":0},{"id":"2441745190","title":"Syndax Pharmaceuticals to Progress into Phase 1b Segment of Revumenib Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2441745190","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441745190?lang=en_us&edition=fundamental","pubTime":"2024-06-06 22:50","pubTimestamp":1717685439,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals  said Thursday it has advanced into the phase 1b segment of its phase 1/2 proof-of-concept trial of revumenib as a monotherapy for patients with relapsed or refractory metastatic microsatellite stable colorectal cancer.The trial's Independent Data Monitoring Committee recommended advancing to the next phase following the favorable safety profile noted in the phase 1a portion of the trial, the company said.The trial aims to evaluate the safety, tolerability, and anti-tumor effects of revumenib in patients with relapsed or refractory metastatic microsatellite stable colorectal cancer.Shares of the company were down 1.1% in recent trading.Price: 19.03, Change: -0.18, Percent Change: -0.94","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNDX","BK4139","PRGS","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"2441857743","title":"Syndax Pharmaceuticals Price Target Maintained With a $41.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441857743","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441857743?lang=en_us&edition=fundamental","pubTime":"2024-06-06 22:22","pubTimestamp":1717683720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 06, 2024 10:22 ET (14:22 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2441717117","title":"Buy Rating Affirmed for Syndax Pharmaceuticals on Clinical Progress and Regulatory Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2441717117","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441717117?lang=en_us&edition=fundamental","pubTime":"2024-06-06 21:35","pubTimestamp":1717680923,"startTime":"0","endTime":"0","summary":"Analyst Edward White from H.C. Wainwright reiterated a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report) and keeping the price target a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-syndax-pharmaceuticals-on-clinical-progress-and-regulatory-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-syndax-pharmaceuticals-on-clinical-progress-and-regulatory-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX","PRGS"],"gpt_icon":0},{"id":"2441715095","title":"BRIEF-Syndax Plans To Advance Into Phase 1B Portion Of Trial Evaluating Revumenib In Relapsed Or Refractory Metastatic MSS CRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2441715095","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441715095?lang=en_us&edition=fundamental","pubTime":"2024-06-06 20:16","pubTimestamp":1717676173,"startTime":"0","endTime":"0","summary":"June 6 (Reuters) - Syndax Pharmaceuticals Inc   :   * SYNDAX ANNOUNCES PLANS TO ADVANCE INTO PHASE 1B PORTION OF TRIAL EVALUATING REVUMENIB IN RELAPSED OR REFRACTORY METASTATIC MSS CRCSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRC","SNDX","BK4113","BK4213","MSS","BK4139"],"gpt_icon":0},{"id":"2441718841","title":"Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2441718841","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441718841?lang=en_us&edition=fundamental","pubTime":"2024-06-06 19:00","pubTimestamp":1717671600,"startTime":"0","endTime":"0","summary":"–IDMC recommendation to advance based on favorable safety profile observed in Phase 1a portion of trial –。WALTHAM, Mass., June 6, 2024 /PRNewswire/ -- Syndax Pharmaceuticals , a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has advanced into the Phase 1b portion of its Phase 1/2 proof-of-concept trial of revumenib, the Company's highly selective, oral menin inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) metastatic microsatellite stable  colorectal cancer . The Company's decision was supported by the trial's Independent Data Monitoring Committee  following its recent pre-planned review of initial data from the Phase 1a portion of the trial.Metastatic microsatellite stable  colorectal cancer  represents the second leading cause of cancer death in the U.S. with an estimated incidence in the relap","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oC0n6PYKYk6YEp28bVXqxg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/17362843347f5cd25e88b726f39fd312","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oC0n6PYKYk6YEp28bVXqxg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/17362843347f5cd25e88b726f39fd312"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/syndax-announces-plans-advance-phase-110000225.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syndax-announces-plans-advance-phase-110000225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNDX","BK4213","CRC","MSS","BK4139","BK4113"],"gpt_icon":0},{"id":"2441224014","title":"Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2441224014","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441224014?lang=en_us&edition=fundamental","pubTime":"2024-06-05 19:00","pubTimestamp":1717585200,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., June 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals , a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 8:40 a.m. ET.A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the CSF-1 receptor. For more information, please visit www.syndax.comor follow the Company onX  andLinkedIn.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9uIK1pTrQYb_oEf9VW8y9Q--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/7c3aa3dad0083dcdf940293b8327c4da","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9uIK1pTrQYb_oEf9VW8y9Q--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/7c3aa3dad0083dcdf940293b8327c4da"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/syndax-announces-participation-goldman-sachs-110000762.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syndax-announces-participation-goldman-sachs-110000762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNDX","BK4137","HCSG","BK4139"],"gpt_icon":0},{"id":"2440041762","title":"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2440041762","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2440041762?lang=en_us&edition=fundamental","pubTime":"2024-06-04 04:05","pubTimestamp":1717445100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., June 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on June 1, 2024 the Company granted inducement awards to purchase up to 499,200 shares of common stock to fifty-three new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gv9cmeAh1EhJEUDbPUon1w--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/42bda435390ec61971a0dfefde873370","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gv9cmeAh1EhJEUDbPUon1w--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/42bda435390ec61971a0dfefde873370"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/syndax-pharmaceuticals-reports-inducement-grants-200500957.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syndax-pharmaceuticals-reports-inducement-grants-200500957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","TQQQ","LU2210150020.SGD","LU2095319765.USD","BK4588","QLD","BK4585","SNDX",".IXIC","QQQ","BK4112","SQQQ","BK4139","MNQmain","NQmain","NDAQ","LU2210149790.SGD","PSQ"],"gpt_icon":0},{"id":"2436995719","title":"Syndax Pharmaceuticals: A Strong Buy on Commercial Opportunity and Near-Term Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2436995719","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436995719?lang=en_us&edition=fundamental","pubTime":"2024-05-17 17:17","pubTimestamp":1715937478,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals (SNDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Zem...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/syndax-pharmaceuticals-a-strong-buy-on-commercial-opportunity-and-near-term-catalysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/syndax-pharmaceuticals-a-strong-buy-on-commercial-opportunity-and-near-term-catalysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2435606926","title":"Syndax Pharmaceuticals Welcomes New Board Member, Passes Resolutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2435606926","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435606926?lang=en_us&edition=fundamental","pubTime":"2024-05-16 04:34","pubTimestamp":1715805242,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc (SNDX) just unveiled an announcement. Syndax Pharmaceuticals has announced the appointment of Aleksandra Rizo, M.D., Ph....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/syndax-pharmaceuticals-welcomes-new-board-member-passes-resolutions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/syndax-pharmaceuticals-welcomes-new-board-member-passes-resolutions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2435664404","title":"Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2435664404","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435664404?lang=en_us&edition=fundamental","pubTime":"2024-05-16 04:05","pubTimestamp":1715803500,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals , a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment ofAleksandra Rizo, M.D., Ph.D., to its Board of Directors.Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr.Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directors.Aleksandra Rizo, M.D., Ph.D., currently serves as President and Chief Executive Officer of Vividion where she joined in 2023 as President, Head of Research and Development. Previously, Dr. Rizo served as Executive Vice President and Chief Medical Officer of Geron Corporation  where she provided leadership and di","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TjYCvOp7_Vb46LJc6_RL8Q--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/61b20eb0785f1aa89eb479ae995e3d61","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TjYCvOp7_Vb46LJc6_RL8Q--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/61b20eb0785f1aa89eb479ae995e3d61"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/syndax-pharmaceuticals-appoints-aleksandra-rizo-200500118.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syndax-pharmaceuticals-appoints-aleksandra-rizo-200500118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2435396908","title":"Syndax Pharmaceuticals (SNDX) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2435396908","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435396908?lang=en_us&edition=fundamental","pubTime":"2024-05-13 10:07","pubTimestamp":1715566063,"startTime":"0","endTime":"0","summary":"In a report released on May 10, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report), wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/syndax-pharmaceuticals-sndx-gets-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/syndax-pharmaceuticals-sndx-gets-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","SNDX","BK4139","SF"],"gpt_icon":0},{"id":"2434060036","title":"Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2434060036","media":"PR Newswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434060036?lang=en_us&edition=fundamental","pubTime":"2024-05-09 19:00","pubTimestamp":1715252400,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals , a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 8:00 a.m. PT/ 11:00 a.m. ET.A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WVBbPUHySQuyzzkofuRMRA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/ff715679d7992ac77cefa2791c86ab17","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WVBbPUHySQuyzzkofuRMRA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/ff715679d7992ac77cefa2791c86ab17"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/syndax-announces-participation-bank-america-110000214.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syndax-announces-participation-bank-america-110000214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765646.SGD","LU0070302665.USD","LU0053666078.USD","BK4504","LU1267930227.SGD","LU1363072403.SGD","LU0640476718.USD","LU0648001328.SGD","IE00B19Z3B42.SGD","LU0648000940.SGD","IE00B7SZLL34.SGD","LU0310800965.SGD","LU1496350171.SGD","LU0106831901.USD","LU0980610538.SGD","BAC","SNDX","BK4585","IE00BZ1G4Q59.USD","LU0098860793.USD","LU1496350502.SGD","IE00BLSP4239.USD","BK4559","BK4588","IE0002270589.USD","LU0208291251.USD","IE00B19Z3581.USD","BK4581","LU0417517546.SGD","LU0234572021.USD","IE00BKVL7J92.USD","BK4139","LU1074936037.SGD","LU2133065610.SGD","LU0130102774.USD","LU0149725797.USD","LU1280957306.USD","LU1162221912.USD","LU0868494617.USD","BK4553","LU0971096721.USD","LU1718418525.SGD","BK4534","LU1668664300.SGD","IE00BLSP4452.SGD","BK4207","LU0256863811.USD","LU0320765489.SGD","LU1201861249.SGD","IE00BBT3K403.USD"],"gpt_icon":0},{"id":"2434166067","title":"Buy Rating for Syndax Pharmaceuticals Amid Strong Financials and Promising Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434166067","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434166067?lang=en_us&edition=fundamental","pubTime":"2024-05-09 18:27","pubTimestamp":1715250466,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Edward White reiterated a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of $41...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-syndax-pharmaceuticals-amid-strong-financials-and-promising-drug-candidate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-syndax-pharmaceuticals-amid-strong-financials-and-promising-drug-candidate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2434614210","title":"Analysts’ Top Healthcare Picks: Elanco Animal Health (ELAN), Syndax Pharmaceuticals (SNDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434614210","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434614210?lang=en_us&edition=fundamental","pubTime":"2024-05-09 17:31","pubTimestamp":1715247060,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Elanco Animal Health (ELAN – Research Report), Synda...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-elanco-animal-health-elan-syndax-pharmaceuticals-sndx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-elanco-animal-health-elan-syndax-pharmaceuticals-sndx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELAN","BK4561","BK4007","BK4139","SNDX","BK4137","HCSG"],"gpt_icon":0},{"id":"2433299667","title":"Syndax Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2433299667","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433299667?lang=en_us&edition=fundamental","pubTime":"2024-05-08 21:32","pubTimestamp":1715175172,"startTime":"0","endTime":"0","summary":"* Syndax Pharmaceuticals Inc    reported a quarterly adjusted loss of 85 cents per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of -59 cen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2433744164","title":"Syndax Pharmaceuticals Q1 2024 GAAP EPS $(0.85) Beats $(0.99) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2433744164","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433744164?lang=en_us&edition=fundamental","pubTime":"2024-05-08 19:17","pubTimestamp":1715167058,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(0.99) by 14.14 percent. This is a 44.07 percent decrease over losses of $(0.59) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38696529/syndax-pharmaceuticals-q1-2024-gaap-eps-0-85-beats-0-99-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2433128741","title":"BRIEF-Syndax Pharmaceuticals Q1 EPS USD -0.85","url":"https://stock-news.laohu8.com/highlight/detail?id=2433128741","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433128741?lang=en_us&edition=fundamental","pubTime":"2024-05-08 19:06","pubTimestamp":1715166409,"startTime":"0","endTime":"0","summary":"May 08 (Reuters) - Syndax Pharmaceuticals Q1 net income USD -72.4 million. * Q1 operating income USD -79.514 million * Q1 operating expenses USD 79.514 million * Q1 cash & investments USD 522 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.1631},{"period":"3month","weight":-0.2104},{"period":"6month","weight":0.1652},{"period":"1year","weight":-0.0682},{"period":"ytd","weight":-0.1023}],"compareEarnings":[{"period":"1week","weight":0.0231},{"period":"1month","weight":0.0339},{"period":"3month","weight":0.0448},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2535},{"period":"ytd","weight":0.1249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.044305},{"month":2,"riseRate":0.625,"avgChangeRate":0.07889},{"month":3,"riseRate":0.625,"avgChangeRate":0.084467},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.000613},{"month":5,"riseRate":0.444444,"avgChangeRate":0.006686},{"month":6,"riseRate":0.555556,"avgChangeRate":0.00194},{"month":7,"riseRate":0.5,"avgChangeRate":-0.000294},{"month":8,"riseRate":0.625,"avgChangeRate":0.063716},{"month":9,"riseRate":0.625,"avgChangeRate":-0.024123},{"month":10,"riseRate":0.25,"avgChangeRate":-0.081003},{"month":11,"riseRate":0.625,"avgChangeRate":0.015744},{"month":12,"riseRate":0.5,"avgChangeRate":0.063584}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Syndax Pharmaceuticals,SNDX,Syndax Pharmaceuticals股票,Syndax Pharmaceuticals股票老虎,Syndax Pharmaceuticals股票老虎国际,Syndax Pharmaceuticals行情,Syndax Pharmaceuticals股票行情,Syndax Pharmaceuticals股价,Syndax Pharmaceuticals股市,Syndax Pharmaceuticals股票价格,Syndax Pharmaceuticals股票交易,Syndax Pharmaceuticals股票购买,Syndax Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction